undamentalytics Newsletter
Sign in

Serina Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Serina Therapeutics, Inc. had total assets of $7.0m, total liabilities of $7.0m and shareholders' equity of −$37,000. It held $3.1m in cash against $2.9m of debt: net cash of $110,000.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents772111843
Receivables0000000——
Total current assets884222866
Total assets10117433977
Accounts payable000101112
Deferred revenue (current)0000—————
Total current liabilities—235910124
Long-term debt————1318———
Total debt00001521303
Total liabilities12591521567
Shareholders' equity772−5−12−38−321−0
Non-controlling interests and other (assets − liabilities − equity)110−0—2036——
Net debt (negative = net cash)−7−7−2−11421−5−4−0
Shares outstanding——————7m—11m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CLDX vs SERIBIO vs SERLSTA vs SER

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Serina Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Serina Therapeutics, Inc.